Abstract: A gear train includes a first gear having teeth meshed with teeth of a second gear. Each tooth of the first gear includes a coast side and a drive side opposed to the coast side. The drive side has a pressure angle that is greater than that of the coast side. The gear train can be part of a powertrain system for a rotorcraft, and can replace a traditional gear train in a retrofit or new build. The first gear is a planet gear and the second gear is a ring gear wherein the planet gear and ring gear are in a planetary gear train configuration.

Abstract: A gear train includes a first gear having teeth meshed with teeth of a second gear. Each tooth of the first gear includes a coast side and a drive side opposed to the coast side. The drive side has a pressure angle that is greater than that of the coast side. The gear train can be part of a powertrain system for a rotorcraft, and can replace a traditional gear train in a retrofit or new build. The first gear is a planet gear and the second gear is a ring gear wherein the planet gear and ring gear are in a planetary gear train configuration.

Abstract: The present invention relates to a process for preparing pyridinyl and pyrimidinyl mono-fluorinated beta keto esters of formula (I): wherein: R1 represents a pyridine ring or a pyrimidine ring, the rings being optionally substituted by a C3-6 cycloalkyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or ahalogenatom; and R3 represents a C1-6 alkyl group; by reacting with fluorine a compound of formula (II) wherein R1, R2 and R3 have the same meaning as defined above.

Abstract: The present invention relates to a process for preparing pyridinyl and pyrimidinyl mono-fluorinated beta keto esters of formula (I): wherein: R1 represents a pyridine ring or a pyrimidine ring, the rings being optionally substituted by a C3-6 cycloalkyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; and R3 represents a C1-6 alkyl group; by reacting with fluorine a compound of formula (II) wherein R1, R2 and R3 have the same meaning as defined above.

Abstract: Methods and apparatus for producing hydrogen are provided. The methods and apparatus utilize reforming catalysts in order to produce hydrogen gas. The reforming catalysts may be platinum group metals on a support material, and they may be located in a reforming reaction zone of a primary reactor. The support material may an oxidic support having a ceria zirconia promoter. The support material may be an oxidic support and a neodymium stabilizer. The support material may also be an oxidic support material and at least one Group IA, Group IIA, manganese, or iron metal promoter. The primary reactor may have a first and second reforming reaction zones. Upstream reforming catalysts located in the first reforming reaction zone may be selected to perform optimally under the conditions in the first reforming reaction zone. Downstream reforming catalysts located in the second reforming reaction zone may be selected to perform optimally under the conditions in the second reforming reaction zone.

Abstract: A pyrimidone derivative represented by formula (I) or a salt thereof: Wherein: R1 represents a hydrogen atom or a C1-6 alkyl group which may be substituted by a C6,10 aryl group; R2 represents a C1-10 alkyl group which may be substituted, a C2-6 alkenyl group which may be substituted, a C3-6 alkynyl group which may be substituted, a C3-6 cycloalkyl group which may be substituted, or a C6-10 ARYL group which may be substituted; or R1 and R2 form together a C2-6 alkylene group which may be substituted; or R1 and R2 form together a chain of formula —(CH2)2—X—(CH2)2— or —(CH2)2—X—(CH2)3— where X represents a oxygen atom, a sulfur atom, or a nitrogen atom which may be substituted; R3 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or halogen atom; and R4 represents a C1-10 alkyl group optionally substituted by a hydroxyl group, amino, C1-6 monoalkylamino group, C2-12 dialkylamino group or C6,10 aryl group which may be substituted.

Abstract: Techniques for providing accurate output measurement and calibration in soft proofing systems incorporate one or more features to promote controlled viewing conditions. For example, a soft proofing system is described in which an administrator can control the proofing process by limiting or restricting the ability to view an image until acceptable viewing conditions have been met. For example, the ability to view the image can be restricted until the viewing station has been calibrated using a calibration device known to support calibration of the viewing station to less than or equal to a maximum magnitude of error. With controlled viewing conditions and, more particularly, controlled calibration conditions, the soft proof reviewers obtain more uniform output. In this manner, the system can provide safeguards to ensure that the images viewed at the viewing station have acceptable color accuracy.

Abstract: Compounds of general formula (I) ##STR1## in which R.sub.1 represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl, (C.sub.3 -C.sub.6)cycloalkylmethyl or phenyl-(C.sub.1 -C.sub.3)alkyl group optionally substituted on the phenyl ring with one or more atoms or groups chosen from halogens and methyl, trifluoromethyl, methoxy and cyano groups, R.sub.2 represents a hydroxyl or alkoxy group or a group of general formula NR.sub.3 R.sub.4 in which R.sub.3 and R.sub.4 each represent a hydrogen atom, an alkyl group, a cycloalkyl group, a cycloalkylmethyl group, a phenyl group, a phenylmethyl group or a pyridyl group, or alternatively R.sub.3 and R.sub.4 form, together with the nitrogen atom, a pyrrolidine or piptzidine ring, and n represents the number 1, 2 or 3.Application in therapy.

Abstract: Compounds of the formula: ##STR1## in which R.sub.1 represents a hydrogen or halogen atom or a methyl or C.sub.1 -C.sub.4 alkoxy group, R'.sub.1 represents a hydrogen or halogen atom, R".sub.1 represents a hydrogen atom or a methoxy group, R.sub.3 represents a C.sub.1 -C.sub.3 alkyl group, R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, or R.sub.3 and R.sub.4 together form, with the adjacent nitrogen atom, a 1,2,3,4-tetrahydroisoquinol-2-yl, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 2,3-dihydro-1H-isoindol-2-yl or 2,3,4,5-tetra-hydro-1H-3-benzazepin-3-yl, group are useful in the treatment of cerebral disorders.

Abstract: The present invention provides a piperidine derivative of formula (I) ##STR1## in which R represents a straight- or branched-chain (C.sub.1 -C.sub.19)alkyl group, a straight- or branched-chain (C.sub.2 -C.sub.19)alkenyl group, a (C.sub.3 -C.sub.6)cycloalkyl group, a cycloalkylmethyl group in which the cycloalkyl moiety has from three to six carbon atoms, a phenyl group which is optionally substituted by a halogen atom or a phenyl methyl group which is optionally substituted by a halogen atom, or an addition salt thereof, in the form of an optically pure enantiomer or of a mixture of enantiomers, a process for making them and their therapeutic application.

Abstract: Compounds of the general formula (I) ##STR1## wherein R.sub.1 represents a hydrogen, fluorine or chlorine atom or a methyl, C.sub.1 -C.sub.3 alkoxy or nitro group; R.sub.3 represents a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group; R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group; or alternatively R.sub.3 and R.sub.4 complete, with the nitrogen atom to which they are attached, a 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 4,5,6,7-tetrahydrothieno[3,2-c]pyrid-6-yl or 2,3-dihydro-1H-isoindol-2-yl group; are useful for the treatment and prevention of cerebral disorders.

Abstract: Compounds of the formula: ##STR1## in which R.sub.1 represents a hydrogen or halogen atom or a methyl or C.sub.1 -C.sub.4 alkoxy group, R'.sub.1 represents a hydrogen or halogen atom, R".sub.1 represents a hydrogen atom or a methoxy group, R.sub.3 represents a C.sub.1 -C.sub.3 alkyl group, R.sub.4 represents a 2,3-dihydro-1H-inden-2-yl, 2,3-dihydro-1H-inden-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, or R.sub.3 and R.sub.4 together form, with the adjacent nitrogen atom, a 1,2,3,4-tetrahydroisoquinol-2-yl, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 5,8-dimethoxy-1,2,3,4-tetrahydroisoquinol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl, 1,2,3,4-tetrahydro-9H-pyrido[4,3-b]indol-3-yl, 4,5,6,7-tetrahydrothieno[2,3-c]pyrid-6-yl, 2,3-dihydro-1H-isoindol-2-yl or 2,3,4,5-tetra-hydro-1H-3-benzazepin-3-yl, group are useful in the treatment of cerebral disorders.

Abstract: Compounds of the formula ##STR1## in which Y represents hydrogen, fluorine, chlorine, methyl or methoxy, R.sub.1 represents phenyl substituted by fluorine, methyl, methoxy, trifluoromethyl or phenyl, or R.sub.1 represents 2-thienyl, R.sub.2 represents methyl, and R.sub.3 represents (C.sub.1 -C.sub.4)-alkyl, or phenyl-(C.sub.1 -C.sub.2)-alkyl optionally substituted on the ring by 2 to 3 methoxy groups, or 2-(2-pyridyl)ethyl, or R.sub.2 and R.sub.3 form, with the adjacent nitrogen, 4-phenyl(1-piperidyl), 4-phenylmethyl(1-piperidyl), 1,2,3,4-tetrahydro-2-isoquinolyl, 6-methoxy-1,2,3,4-tetrahydro-2-isoquinolyl, 5,8-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl, 6,7-dimethoxy 1,2,3,4-tetrahydro-2-isoquinolyl, 2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl, or 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl, and X represents carbonyl or sulphonyl, and their salts are useful as neuroprotective and antiiischaemic agents.

Abstract: A compound which is an ethanol or ethanone derivative of general formula (I) ##STR1## in which X represents CO or CHOH, or is an addition salt thereof with an acid, and, when X represents CHOH, is in the form of a pure enantiomer or a mixture of enantiomers, can be used for the treatment and prevention of cerebral disorders.

Abstract: A compound, in the form of a pure optical isomer or a mixture thereof, of formula (I): ##STR1## in which: Z represents a group of formula --CH.sub.2 --, --C(CH.sub.3).sub.2 --, --CH.dbd.CH--, --(CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 --, --NH-- or --N(CH.sub.3)CH.sub.2 --, in which the nitrogen is bonded to the carbonyl group;R1 represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;R2 represents hydrogen or a methyl group; andR3 represents:a phenoxy group which is unsubstituted or substituted by a halogen or a methyl group,a naphthyloxy group,a phenylmethyl group substituted by a halogen or a methyl group,an unsubstituted phenylmethyl group when Z does not representa group of formula --CH.dbd.CH-- or --(CH.sub.2).sub.

Abstract: A quinolinone derivative which is a compound of formula (I): ##STR1## in which: R.sub.1 and R.sub.2 are each, independently of one another, a hydrogen or halogen atom or a (C.sub.1-4)alkyl radical;R.sub.3 is a hydrogen atom or a (C.sub.1-4)alkyl radical;R.sub.4 is an unsubstituted or substituted naphthyl, tetrahydronaphthyl, benzyl, phenyl, pyridyl, isoquinolyl or benzoyl radical; and X and Y are each a hydrogen atom or together form a bond; or a pharmaceutically acceptable acid addition salt thereof and, when X and Y are each a hydrogen atom, the diastereoisomers and enantiomers thereof.

Abstract: A pyrimidinedione derivative which is a compound of formula (I): ##STR1## in which: R1 denotes hydrogen, a halogen, a methyl group or a methoxy group,R2 denotes hydrogen, a C.sub.1 -C.sub.4 alkyl group or a benzyl group,n denotes 2, 3 or 4,X denotes a CH group or nitrogen, andR3 denotes hydrogen, a halogen or a methoxy group when X denotes a CH group, with the proviso that R3 denotes hydrogen when X denotes nitrogen,or a pharmacologically acceptable acid addition salt thereof.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R.sub.2 is hydroxyl or methoxy in the 4-position and R.sub.3 is hydrogen, R.sub.1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl,R.sub.2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy,R.sub.3 is hydrogen or alkyl,R.sub.4 is alkyl (in which case the compounds are (.+-.)-erythro) or when R.sub.3 represents hydrogen, R.sub.4 may also be hydrogen, and R.sub.5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein:(a) one of R.sub.1 and R.sub.2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R.sub.3 and R.sub.5 are hydrogen and wherein:(b) R.sub.1 is in the 4-position and is halogen, R.sub.4 is methyl and R.sub.

Abstract: Compounds of general formula (I) ##STR1## wherein R1 represents a phenyl, halophenyl, methylphenyl, ethylphenyl, methoxyphenyl, trifluoromethylphenyl or naphthyl group, R2 represents hydrogen or a methyl or phenyl group, and R3 represents hydrogen or a benzyl group, except compounds in which R1 is a phenyl or 4-fluorophenyl group, R2 is hydrogen and R3 is hydrogen or a benzyl group, and their pharmaceutically acceptable acid addition salts have useful anti-depressant and anti-ischaemic properties.

Abstract: Pyridine derivatives of the general formula (I) ##STR1## in which X is --O-- or --NH--, R.sub.1 is a phenyl group optionally substituted by one or two halogen atoms or a methyl, ethyl, trifluoromethyl, methoxy or phenyl group or, when R.sub.2 is not a benzyl group, an amino group, or is a naphthyl or benzodioxanyl group, and R.sub.2 is hydrogen or a benzyl group, or when X is --O--, R.sub.2 can also be a methyl or ethyl group, and their pharmaceutically acceptable acid addition salts are useful as antianoxics.